US5643604A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Parenteral dosage form
Assignee: Aplicaciones Farmaceuticas SA de CV
•
Filing: 1993-07-14
•
Granted: 1997-07-01
•
Expires: 2013-07-14
Abstract
Abstract Delayed-release formulation intended for administration by parenteral injection, consisting of solid calibrated microspheres (5-300 μm) comprising a pharmaceutically active substance (for example: morphine) contained in spherical structures determined by one or more which are pharmacologically inactive carrier substances (for example: cholesterol), naturally present in the receiving organism, which are pharmacodynamically inactive at the administered doses of said dosage form, having a melting point greater than 60° C. and stable in the solid state in the receiving physiological medium. The dosage form makes it possible to slow and prolong the effect of active substances which are too rapidly soluble in physiological medium (which act on the central nervous or neurovegetative system, such as vasedilators, anti-histaminics, hormones, contraceptives and the like).
Inventors
- 👤 Juan Angeles Uribe
- 👤 Josue Garza Flores
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:13
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1617; A61K9/48; A61K9/50
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
94 words
A pharmaceutical formulation suitable for compounding for parenteral administration to a mammal comprising solid, non-porous microspheres, said microspheres having a diameter of between 5 and 300 μm, wherein said microspheres consist of cholesterol as a carrier substance and particles of a pharmaceutically active substance homogeneously disbursed within said cholesterol carrier substance wherein said microspheres are obtained by spraying said cholesterol in the melted state in which said pharmacologically active substance is either in the dissolved state or in the form of particles less than 5 μm, to form droplets and rapidly freezing said droplets.
Claim 2
Dependent Claim
94 words
A pharmaceutical formulation suitable for compounding for parenteral administration to a mammal comprising solid, non-porous microspheres, said microspheres having a diameter of between 5 and 300 μm, wherein said microspheres consist of cholesterol as a carrier substance and particles of a pharmaceutically active substance homogeneously disbursed within said cholesterol carrier substance wherein said microspheres are obtained by spraying said cholesterol in the melted state in which said pharmacologically active substance is either in the dissolved state or in the form of particles less than 5 μm, to form droplets and rapidly freezing said droplets.
Claim 3
Dependent Claim
19 words
The pharmaceutical formulation of claim 1, wherein the average diameter of said microspheres is between 10 and 100 μm.
Claim 4
Dependent Claim
14 words
The pharmaceutical formulation of claim 2, wherein said microspheres further comprise pharmaceutically active additives.
Claim 5
Dependent Claim
34 words
The pharmaceutical formulation of claim 1, wherein said carrier substance is chemically stable when melted, and wherein said pharmaceutically active substance is chemically stable in said carrier substance when said carrier substance is melted.
Claim 6
Dependent Claim
24 words
The pharmaceutical formulation of claim 4, wherein said carrier substance is selected from the group consisting of coprosterol, glycocholic acid, cholesterol, and cholesterol esters.
Claim 7
Dependent Claim
34 words
The pharmaceutical formulation of claim 1, wherein more than 70% of said microspheres have diameters of between 70% and 130% of a specified diameter, and said specified diameter is between 5 and 300 μm.
Claim 8
Dependent Claim
26 words
The pharmaceutical formulation of claim 1 wherein said pharmaceutically active substance comprises a steroidal sexual hormone capable of a contraceptive effect when administered to a mammal.
Claim 9
Dependent Claim
23 words
The pharmaceutical formulation of claim 7 wherein the steroidal sexual hormone is selected from among the group consisting of progesterone, testosterone, and 17-β-estradiol.
Claim 10
Dependent Claim
21 words
The pharmaceutical formulation of claim 8 wherein the carrier substance is selected from the group consisting of cholesterol and cholesterol esters.
Claim 11
Dependent Claim
24 words
The pharmaceutical formulation of claim 1 wherein the active agent is a steroidal medicinal product useful in the prevention of osteoporosis in menopausal women.
Claim 12
Dependent Claim
116 words
A method for the manufacture of a pharmaceutical formulation of claim 1 for parenteral administration by injection, comprising the step of combining at least one pharmaceutically active substance with at least one pharmacologically inactive carrier substance into solid, non-porous microspheres wherein the pharmaceutically active substance is homogeneously dispersed within the carrier substance, said microspheres having a diameter of between 5 and 300 μm, wherein said carrier substance is naturally present in mammalian organisms and is stable at temperatures below 60° C., and wherein the kinetics of dissolution of said carrier substance in a mammalian organism into which said microspheres have been injected is slower than the kinetics of release of said active substance in said organism.
Claim 13
Dependent Claim
28 words
The method of claim 11, wherein said microspheres are in the form of a powder, and are prepared into a suspension in a pharmaceutically acceptable liquid suspension medium.
Claim 14
Dependent Claim
19 words
The method of claim 12, wherein said liquid suspension medium is selected from the group consisting of aqueous solutions.
Claim 15
Dependent Claim
14 words
The method of claim 12, wherein said liquid suspension medium is a saline solution.
Claim 16
Dependent Claim
31 words
The method of claim 11, wherein said microspheres are combined with a pharmaceutically acceptable liquid suspension medium in which said active substance is at least partially insoluble to form a suspension.
Claim 17
Dependent Claim
34 words
The method of claim 11, wherein said active substance is 17-β-estradiol and said carrier substance is cholesterol, and wherein said microspheres act as a contraceptive when administered to an organism in an effective amount.
Claim 18
Dependent Claim
47 words
The method of claim 11, further comprising the step of separating said microspheres into calibrated fractions according to particle size, wherein more than 70% of said microspheres have diameters between 70% and 130% of a specified diameter, and said specified diameter is between 5 and 300 μm.
Claim 19
Dependent Claim
47 words
The method of claim 12, further comprising the step of separating said microspheres into calibrated fractions according to particle size, wherein more than 70% of said microspheres have diameters between 70% and 130% of a specified diameter, and said specified diameter is between 5 and 300 μm.
Claim 20
Dependent Claim
47 words
The method of claim 16, further comprising the step of separating said microspheres into calibrated fractions according to particle size, wherein more than 70% of said microspheres have diameters between 70% and 130% of a specified diameter, and said specified diameter is between 5 and 300 μm.
Claim 21
Dependent Claim
105 words
A method for parenteral administration of pharmaceutically active substances, of claim 1, comprising parenteral injection of solid, non-porous microspheres into a mammalian organism, said microspheres comprising at least one pharmaceutically active substance homogeneously dispersed within a pharmacologically inactive carrier substance, said microspheres having a diameter of between 5 and between 300 μm, and wherein said carder substance is naturally present in said organism and is stable at temperatures below 60° C., and wherein the kinetics of dissolution for said carrier substance in said organism into which said microspheres have been injected is slower than the kinetics of release of said active substance in said organism.
Claim 22
Dependent Claim
47 words
The method of claim 20, further comprising the step of separating said microspheres into calibrated fractions according to particle size, wherein more than 70% of said microspheres have diameters between 70% and 130% of a specified diameter, and said specified diameter is between 5 and 300 μm.
References Cited (Backward Citations)
US3691090A
Cited
US3773919A
Cited
US3937668A
Cited
US3773519A
Cited
US3982537A
Cited
US4147767A
Cited
US4158707A
Cited
US4357259A
Cited
US4244949A
Cited
US4331654A
Cited
US4384975A
Cited
US4349530A
Cited
US4711783A
Cited
US4492720A
Cited
US4963367A
Cited
US4675236A
Cited
US4675173A
Cited
US4745907A
Cited
EP0210875A2
Cited
EP0257368A1
Cited
US4837381A
Cited
US4882164A
Cited
US4748024A
Cited
WO1988007816A1
Cited
US4892734A
Cited
US5019400A
Cited
US5085864A
Cited
US5360616A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-06-30 | 2000-12-30 | 2001-07-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-06-30 | 2004-12-30 | 2005-07-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-06-30 | 2008-12-30 | 2009-07-01 | $7700.00 | Window Closed / Lapsed |